Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 423 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Botulinum toxin(Botox) Clear all

Conditions: Overactive Bladder
Interventions: Botox, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Bladder Syndrome
Interventions: Xeomin 100 UNT Injection, Botox 100 UNT Injection; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Upper Limb Essential Tremor (UL ET)
Interventions: BOTOX, Placebo for BOTOX; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 36
States / cities: Hoover, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally; Drug
Lead sponsor: li nguyen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Lower Back Pain
Interventions: Placebo, AbobotulinumtoxinA Treatment; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Platysma Prominence
Interventions: BOTOX® purified neurotoxin complex, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 4 more

Conditions: Blepharospasm
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 14
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more

Conditions: Nervous System Disorders
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more

Conditions: COPD
Interventions: OnabotulinumtoxinA, Placebo; Drug · Other
Lead sponsor: RMW Testing; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Peyronie's Disease
Interventions: 100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A; Drug · Other
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Migraine
Interventions: onabotulinumtoxinA, Topiramate, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Pain
Interventions: Lumbar sympathetic block with Botulinum Toxin type A; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Elkridge, Maryland • Boston, Massachusetts • Southfield, Michigan + 1 more

Conditions: Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions: Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more

Conditions: Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more

Conditions: Glabellar Frown Lines
Interventions: PrabotulinumtoxinA, Onabotulinum toxin A; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: botulinum toxin Type A; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Upper Limb Spasticity
Interventions: AboBoNT-A, OnaBoNT-A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Scar, Hypertrophic Scar
Interventions: Botulinum Toxin, Normal saline; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Spastic Hemiparesis
Interventions: Botulinum toxin type A, GSC; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more

Conditions: Traumatic Brain Injury
Interventions: BoNT A; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tears; Excess, Eyelid Spasm
Interventions: Botulinum toxin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Esophageal Achalasia, Esophageal Spasm, Diffuse, Esophageal Motility Disorders
Interventions: peroral endoscopic myotomy, Botulinum toxin injection; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

ASIS for Botox in Upper Limb Spasticity

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

BOTOX® for the Treatment of Platysma Prominence

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

Dysport® Adult Upper Limb Spasticity

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

H-22411: BOTOX® for Peyronie's Disease

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.

Phase IV-Cervical Dystonia-INTEREST IN CD2

Refractory Urge Incontinence and Botox Injections

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders